Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia

被引:39
作者
Addington, D
Addington, J
Patten, S
Remington, G
Moamai, J
Labelle, A
Beauclair, L
机构
[1] Univ Calgary, Foothills Med Ctr, Dept Psychiat, Calgary, AB T2N 2T9, Canada
[2] Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 2T9, Canada
[3] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[4] Univ Ottawa, Dept Psychiat, Hull, PQ, Canada
[5] McGill Univ, Dept Psychiat, Montreal, PQ, Canada
关键词
D O I
10.1097/00004714-200202000-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effectiveness of selective serotonin reuptake inhibitors for depression in remitted schizophrenia has not been clearly demonstrated. A randomized, double-blind, prospective placebo-controlled study was performed of 48 subjects meeting DSM-IV criteria for both schizophrenia in remission and for a major depressive episode. Twenty-seven patients were randomized to placebo and 21 to sertraline. All subjects had a 1-week anticholinergic phase before randomization. The treatment duration was 6 weeks. Sertraline was started at 50 mg/day; this could be increased to 100 mg after 4 weeks for an inadequate response. There were no statistically significant differences in symptoms between the two groups at randomization. There were no differences in outcome between treatment groups. In both groups, between 40% and 50% of subjects showed a 50% reduction in depression score. This study does not provide support for the efficacy of sertraline in the treatment of depression in remitted schizophrenia. The small sample size limits the strength of the conclusions that can be drawn from this study. The study design called for a sample size of 96 on the basis of an expected placebo response rate of 30%. Recruitment for the study was difficult because of the placebo design. The placebo response was 50%. Clinicians and patients underestimate the strength of the placebo response and may overestimate the risk of participating in such a study. Testing the efficacy of widely accepted but poorly evaluated treatments should be a research priority. Future studies require a larger sample size and longer duration of treatment.
引用
收藏
页码:20 / 25
页数:6
相关论文
共 32 条
[1]   RELIABILITY AND VALIDITY OF A DEPRESSION RATING-SCALE FOR SCHIZOPHRENICS [J].
ADDINGTON, D ;
ADDINGTON, J ;
MATICKATYNDALE, E ;
JOYCE, J .
SCHIZOPHRENIA RESEARCH, 1992, 6 (03) :201-208
[2]   SPECIFICITY OF THE CALGARY-DEPRESSION-SCALE FOR SCHIZOPHRENICS [J].
ADDINGTON, D ;
ADDINGTON, J ;
MATICKATYNDALE, E .
SCHIZOPHRENIA RESEARCH, 1994, 11 (03) :239-244
[3]   Readiness to stop smoking in schizophrenia [J].
Addington, J ;
elGuebaly, N ;
Addington, D ;
Hodgins, D .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1997, 42 (01) :49-52
[4]  
Bassett A, 1998, CAN J PSYCHIAT, V43, p25S
[5]  
BECKER RE, 1983, AM J PSYCHIAT, V140, P208
[6]  
CHOUINARD G, 1980, CAN J NEUROL SCI, V7, P233
[7]  
Hamilton M., 1967, British Journal of Social and Clinical Psychology, V6, P278
[8]  
HARRISON W, 1988, PSYCHOPHARMACOL BULL, V24, P9
[9]  
Herz MI, 1997, AM J PSYCHIAT, V154, P1
[10]  
HOGARTY GE, 1995, ARCH GEN PSYCHIAT, V52, P29